Bi Jinling, Liu Haiyuan, Huang Yong
Department of Oncology, The Second People's Hospital of He Fei, He Fei, An Hui, People's Republic of China.
Int Med Case Rep J. 2017 Jul 4;10:223-227. doi: 10.2147/IMCRJ.S137484. eCollection 2017.
The aim of this study was to explore the effect of apatinib in the treatment of metastatic renal cell carcinoma (mRCC) and related adverse events. A case of mRCC was reported which recurred after surgery and roferon treatment. The patient was treated with apatinib at a dose of 500 mg orally, twice daily, 28 days/cycle. The metastatic lesions improved based on computed tomography after apatinib administration in the fourth and eighth month. The progression-free survival of the patient had increased almost to 8 months. The patient showed a good tolerance with only an adverse effect of mild-to-moderate hand-foot syndrome which was managed well. Apatinib is an option for mRCC after previous treatment. However, more and larger trials are still needed.
本研究旨在探讨阿帕替尼治疗转移性肾细胞癌（mRCC）的疗效及相关不良事件。报告了1例mRCC患者，该患者术后及使用干扰素治疗后复发。患者接受阿帕替尼治疗，口服剂量为500 mg，每日2次，每28天为1个周期。在服用阿帕替尼后的第4个月和第8个月，根据计算机断层扫描结果，转移病灶有所改善。患者的无进展生存期几乎增加到了8个月。患者耐受性良好，仅出现轻度至中度手足综合征这一不良事件，且处理得当。阿帕替尼是既往治疗后mRCC的一种选择。然而，仍需要更多且规模更大的试验。
